Completed PHASE3 INTERVENTIONAL 3-arm NCT01753570

Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)

A Phase 3 Study of MP-424 in Combination With IFN Beta and RBV, in Subjects With Genotype 1/2 Hepatitis C, Who Are Treatment-Naïve or Have Received Interferon Based Therapy

Sponsor: Tanabe Pharma Corporation

Conditions Chronic Hepatitis C(CHC)

Interventions IFN beta(24 weeks) IFN beta(48 weeks) MP-424 RBV(24 weeks) RBV(48 weeks)

Updated 9 times since 2017 Last updated: Dec 15, 2025 Started: Dec 31, 2012 Primary completion: Oct 31, 2015 Completion: Oct 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Chronic Hepatitis C(CHC), this trial is completed. The trial is conducted by Tanabe Pharma Corporation and has accumulated 9 data snapshots since 2012. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

9 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE3
Jan 2026 — Feb 2026 [monthly]

Completed PHASE3
Sep 2025 — Jan 2026 [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Nov 2018 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Nov 2018 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tanabe Pharma Corporation
Toray Industries, Inc

Data source: Tanabe Pharma Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kawasaki, Japan